Treatment for hemophilia A consists of injecting the missing Factor VIII by I.V. to prevent or stop the bleeding. A majority of the complications of this treatment are the development of antibodies against FVIII, called inhibitors.
The development of an anti-FVIII inhibitor leads to episodes of bleeding that are difficult to control.
The activity of the inhibitor is measured by a Bethesda test and is expressed in BU.
1BU neutralizes 50% of the activity of FVIII for hemophilia A.
It allows the determination of the titre of a functional FVIII inhibitor to contribute to the clinical management of congenital hemophilia A in patients over 2 years of age.
The kit provides imidazole buffered plasma, imidazole buffer, and negative and positive controls that improve the repeatability and repoducibility of the assay method.
This kit must be associated with a measurement of the activity of Factor VIII by chronometric method on citrated human plasma.
Expiration date of 3 years from the date of manufacture with storage at -70 ° C.
- Each kit contains five sets of vials, including positive and negative FVIII inhibitor controls
- Excellent repeatability and reproducibility
- Suitable for multicenter clinical studies
- Excellent linearity
- Convenient frozen format, ready to use in minutes, no reconstitution errors
- 10 vials x pool of normal plasma buffered with imidazole (1.5 mL)
- 10 vials x imidazole buffer containing bovine serum albumin (1.5 mL)
- 5 vials x negative control (0.5 mL)
- 5 vials x positive control (0.5 mL)
